Eurofins Scientific SE (EPA:ERF)

Market Cap	10.86B +6.7%
Revenue (ttm)	7.30B +5.0%
Net Income	416.10M +16.8%
EPS	2.23 +21.9%
Shares Out	175.63M
PE Ratio	27.74
Forward PE	14.89
Dividend	0.72 (1.16%)
Ex-Dividend Date	Apr 28, 2026

Volume	34,985
Open	61.76
Previous Close	61.86
Day's Range	61.68 - 62.42
52-Week Range	54.86 - 74.32
Beta	0.85
Analysts	Hold
Price Target	70.89 (+14.9%)
Earnings Date	May 7, 2026

About Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product tes...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1987
• Employees: 65,694
• Stock Exchange: Euronext Paris
• Ticker Symbol: ERF

Financial Performance

In 2025, Eurofins Scientific SE's revenue was 7.30 billion, an increase of 4.96% compared to the previous year's 6.95 billion. Earnings were 416.10 million, an increase of 16.78%.

Analyst Summary

According to 14 analysts, the average rating for ERF stock is "Hold." The 12-month stock price target is €70.89, which is an increase of 14.90% from the latest price.

Price Target

€70.89

(14.90% upside)

Analyst Consensus: Hold